Risk stratification and personalized therapy in lupus pregnancies

狼疮妊娠的风险分层和个性化治疗

• 批准号: 462095
• 负责人: Vinet Evelyne
• 金额: $ 55.17万
• 依托单位: Research Institute of the McGill University Health Centre
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2027-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=462095&lang=en
• 关键词: Adverse Pregnancy Outcomes; Antiphosphatidylserine/Prothrombin Antibodies (Aps/Pt); Antiphospholipid Antibodies; Disease Flare; Lupus Low Disease Activity State (Lldas); Placenta-Mediated Complications; Pregnancy; Risk Factors; Systemic Lupus Erythematosu

With recent advances in lupus treatment, the vast majority of affected women can now consider pregnancy. However, pregnant women with lupus still face an unacceptably high risk of maternal and fetal complications. Therefore, the overarching aim of our pro

随着狼疮治疗的最新进展，绝大多数受影响的女性现在可以考虑怀孕。然而，患有狼疮的孕妇仍然面临着令人无法接受的母婴并发症的高风险。因此，我们专业人员的首要目标是